Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|April 29, 2015
[Analysis of the karyotype abnormalities and its prognostic in 298 patients with myelodysplastic syndrome]Xuefen Yan, Juying Wei, Jinghan Wang, et al.
Hematological Oncology|October 31, 2022
Co-mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndromeYanling Ren, Wei Lang, Chen Mei, et al.
Journal of Cancer|April 15, 2021
Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 studyLi Ye, Chen Mei, Yanling Ren, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|October 20, 2015
[Clinical and cytogenetic study of chromosome 1 abnormality in myelodysplastic syndrome]Wei Wang, Zhimei Chen, Mengxia Yu, et al.
Cancer Medicine|May 19, 2026
Finite-Duration Venetoclax/Azacitidine Followed by Umbilical Cord Blood Infusion Improves Outcomes in Frail Elderly Patients With Untreated Acute Myeloid Leukemia-A Pilot StudyLi Ye, Mixue Xie, Gaixiang Xu, et al.
Asia-Pacific Journal of Clinical Oncology|February 8, 2020
TP53 mutations are associated with very complex karyotype and suggest poor prognosis in newly diagnosed myelodysplastic syndrome patients with monosomal karyotypeYanling Ren, Jinghan Wang, Hua Zhang, et al.
Journal of Translational Medicine|January 17, 2025
The molecular prognostic scoring system for normal karyotype myelodysplastic syndromesWei Wang, Yudi Zhang, Wenli Yang, et al.
Leukemia & Lymphoma|November 10, 2018
The relation of SF3B1 mutation and intracellular iron in myelodysplastic syndrome with less than 5% bone marrow blastsLiya Ma, Yingwan Luo, Lingxu Jiang, et al.
Leukemia & Lymphoma|January 9, 2019
Decitabine for myelodysplastic syndromes: dose comparison in a real world clinical settingYanling Ren, Huifang Jiang, Fangjing Shi, et al.
Blood Cells, Molecules & Diseases|April 22, 2019
Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapyLi Ye, Yanling Ren, Xinping Zhou, et al.
Pageof 6